Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial
Objective. Report of prespecified and post hoc subgroup analyses of a randomized, controlled trial comparing telmisartan 80 mg/hydrochlorothiazide 25 mg (T80/H25) combination therapy with T80 monotherapy, according to the presence of cardiovascular disease (CVD) risk factors. Methods. Hypertensive p...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.1155/2013/749830 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556749567033344 |
|---|---|
| author | Harold Bays Pingjin Gao Birgit Völker Michaela Mattheus Luis M. Ruilope Dingliang Zhu |
| author_facet | Harold Bays Pingjin Gao Birgit Völker Michaela Mattheus Luis M. Ruilope Dingliang Zhu |
| author_sort | Harold Bays |
| collection | DOAJ |
| description | Objective. Report of prespecified and post hoc subgroup analyses of a randomized, controlled trial comparing telmisartan 80 mg/hydrochlorothiazide 25 mg (T80/H25) combination therapy with T80 monotherapy, according to the presence of cardiovascular disease (CVD) risk factors. Methods. Hypertensive patients were randomized (2 : 1) to receive T80/H25 or T80 for 6 weeks, following a 1-week, low-dose, and run-in period. Systolic blood pressure (SBP) and diastolic BP reductions and BP goal achievement were evaluated in patients with CVD risk factors: presence of diabetes mellitus (DM), renal impairment, increased body mass index (BMI), and 10-year estimated risk for coronary heart disease (CHD). Results. In total, 888 patients received treatment. Overall, T80/H25 therapy significantly reduced SBP more than T80 monotherapy, irrespective of patient subgroup. In patients with DM, renal impairment, high BMI, and high CHD risk, BP goal achievement rates (<140/90 mm Hg) at Week 7, among those treated with T80/H25, were 52.8%, 52.8%, 50.6%, and 38.5%, respectively. More patients with DM reached a guideline-based BP goal (<130/80 mm Hg) at 7 weeks with T80/H25 than with T80 monotherapy (16.7% versus 8.8%). Rates of treatment-related adverse events were low and comparable across patient subgroups. Conclusions. Antihypertensive treatment with T80/H25 single-pill combination is effective and generally well tolerated, irrespective of the presence of CVD risk factors. |
| format | Article |
| id | doaj-art-756da68732774cb59a0065b98fbf0723 |
| institution | Kabale University |
| issn | 2090-0384 2090-0392 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-756da68732774cb59a0065b98fbf07232025-02-03T05:44:30ZengWileyInternational Journal of Hypertension2090-03842090-03922013-01-01201310.1155/2013/749830749830Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled TrialHarold Bays0Pingjin Gao1Birgit Völker2Michaela Mattheus3Luis M. Ruilope4Dingliang Zhu5Louisville Metabolic and Atherosclerosis Research Center Inc. (L-MARC), 3288 Illinois Avenue, Louisville, KY 40213, USAShanghai Ruijin Hospital, Shanghai 200025, ChinaBoehringer Ingelheim Pharma GmbH & Co. KG, 55216 Ingelheim, GermanyBoehringer Ingelheim Pharma GmbH & Co. KG, 55216 Ingelheim, GermanyHospital 12 de Octubre, 28041 Madrid, SpainShanghai Ruijin Hospital, Shanghai 200025, ChinaObjective. Report of prespecified and post hoc subgroup analyses of a randomized, controlled trial comparing telmisartan 80 mg/hydrochlorothiazide 25 mg (T80/H25) combination therapy with T80 monotherapy, according to the presence of cardiovascular disease (CVD) risk factors. Methods. Hypertensive patients were randomized (2 : 1) to receive T80/H25 or T80 for 6 weeks, following a 1-week, low-dose, and run-in period. Systolic blood pressure (SBP) and diastolic BP reductions and BP goal achievement were evaluated in patients with CVD risk factors: presence of diabetes mellitus (DM), renal impairment, increased body mass index (BMI), and 10-year estimated risk for coronary heart disease (CHD). Results. In total, 888 patients received treatment. Overall, T80/H25 therapy significantly reduced SBP more than T80 monotherapy, irrespective of patient subgroup. In patients with DM, renal impairment, high BMI, and high CHD risk, BP goal achievement rates (<140/90 mm Hg) at Week 7, among those treated with T80/H25, were 52.8%, 52.8%, 50.6%, and 38.5%, respectively. More patients with DM reached a guideline-based BP goal (<130/80 mm Hg) at 7 weeks with T80/H25 than with T80 monotherapy (16.7% versus 8.8%). Rates of treatment-related adverse events were low and comparable across patient subgroups. Conclusions. Antihypertensive treatment with T80/H25 single-pill combination is effective and generally well tolerated, irrespective of the presence of CVD risk factors.http://dx.doi.org/10.1155/2013/749830 |
| spellingShingle | Harold Bays Pingjin Gao Birgit Völker Michaela Mattheus Luis M. Ruilope Dingliang Zhu Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial International Journal of Hypertension |
| title | Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial |
| title_full | Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial |
| title_fullStr | Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial |
| title_full_unstemmed | Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial |
| title_short | Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial |
| title_sort | efficacy of single pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg in patients with cardiovascular disease risk factors a prospective subgroup analysis of a randomized double blind and controlled trial |
| url | http://dx.doi.org/10.1155/2013/749830 |
| work_keys_str_mv | AT haroldbays efficacyofsinglepillcombinationoftelmisartan80mgandhydrochlorothiazide25mginpatientswithcardiovasculardiseaseriskfactorsaprospectivesubgroupanalysisofarandomizeddoubleblindandcontrolledtrial AT pingjingao efficacyofsinglepillcombinationoftelmisartan80mgandhydrochlorothiazide25mginpatientswithcardiovasculardiseaseriskfactorsaprospectivesubgroupanalysisofarandomizeddoubleblindandcontrolledtrial AT birgitvolker efficacyofsinglepillcombinationoftelmisartan80mgandhydrochlorothiazide25mginpatientswithcardiovasculardiseaseriskfactorsaprospectivesubgroupanalysisofarandomizeddoubleblindandcontrolledtrial AT michaelamattheus efficacyofsinglepillcombinationoftelmisartan80mgandhydrochlorothiazide25mginpatientswithcardiovasculardiseaseriskfactorsaprospectivesubgroupanalysisofarandomizeddoubleblindandcontrolledtrial AT luismruilope efficacyofsinglepillcombinationoftelmisartan80mgandhydrochlorothiazide25mginpatientswithcardiovasculardiseaseriskfactorsaprospectivesubgroupanalysisofarandomizeddoubleblindandcontrolledtrial AT dingliangzhu efficacyofsinglepillcombinationoftelmisartan80mgandhydrochlorothiazide25mginpatientswithcardiovasculardiseaseriskfactorsaprospectivesubgroupanalysisofarandomizeddoubleblindandcontrolledtrial |